SynthesisEmerging microbes & infections2026
Maternal Chikungunya virus infection and pregnancy outcomes: a global systematic review and meta-analysis of vertical transmission dynamics and associated morbidity.
Synthesis in Emerging microbes & infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Virucidal Efficacy of Holder Pasteurization of Breast Milk in a Portable Device.Pathogens (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chikungunya virus (CHIKV) infection during pregnancy presents a major threat to maternal-fetal health, yet a comprehensive global assessment of vertical transmission risks and perinatal outcomes remains scarce. To provide a comprehensive evidence synthesis, we conducted a systematic review and meta-analysis, prospectively registered in PROSPERO (CRD420251164423). We screened studies published up to October 20, 2025, and included 57 observational studies for qualitative synthesis, with 27 studies pooled in meta-analyses. The pooled vertical transmission rate was 18.1%, revealing a pronounced gestational-age gradient: rates were low in the first (3.9%) and second (1.2%) trimesters but surged dramatically during the third trimester (36.5%) and the intrapartum period (49.1%). Adverse pregnancy outcomes occurred in 11.3% of infected women, with abnormal fetal heart rate (44.9%) and stillbirth (22.0%) being the most frequent. Among neonates, 36.5% experienced adverse outcomes, commonly including feeding difficulties (79.4%), fever (68.9%), and thrombocytopenia (57.2%); neonatal mortality reached 6.9%. Crucially, meta-analysis of comparative studies demonstrated that maternal CHIKV infection was associated with a more than two-fold higher risk of adverse perinatal outcomes (OR = 2.28), with particularly robust associations identified for abnormal fetal heart rate (OR = 5.07) and delayed neurodevelopment (OR = 11.98). This study underscores that maternal CHIKV infection, especially during late gestation, substantially elevates the risks of vertical transmission and severe perinatal complications. Consequently, our findings strongly advocate for the implementation of enhanced prenatal surveillance and systematic postnatal assessment protocols in CHIKV-endemic regions to mitigate adverse outcomes and guide public health interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.